Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
Lobbying · US Senate · Influence
Lobbying Analysis
Lobbying · US Senate · Influence
Nuvalent, Inc. has no lobbying expenses in our database.
| FY | Quarter | Lobby Expense [in mil. $] | Filing | Report Time |
|---|---|---|---|---|
| No data |